Patents Assigned to Otsuka Pharmaceutical Co., Ltd.
  • Publication number: 20240158380
    Abstract: Provided are an amorphous solid dispersion containing compound (I), an amorphous form containing compound (I) and an organic acid, an amorphous solid dispersion containing the amorphous form, a pharmaceutical composition containing the amorphous form or the amorphous solid dispersion, and preparation methods for these.
    Type: Application
    Filed: February 16, 2022
    Publication date: May 16, 2024
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Naoki Kamada, Motoyasu YOSHIMURA, Mariko KIMOTO
  • Publication number: 20240156811
    Abstract: The present invention provides a medicament having a wider treatment spectrum, causing a fewer side effects and superior in tolerability and safety, as compared to known typical antipsychotic agents and atypical antipsychotic agents. The present invention related to a medicament containing (1) a compound which is 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof, and (II) at least one drug selected from the group consisting of a mood stabilizer, a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a serotonin and norepinephrine reuptake inhibitor, a noradrenergic and specific serotonergic antidepressant, an antianxiety drug, a tricyclic antidepressant, a tetracyclic antidepressant, an antipsychotic drug and an anti-ADHD drug, in combination.
    Type: Application
    Filed: August 25, 2023
    Publication date: May 16, 2024
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Tsuyoshi HIROSE, Kenji MAEDA, Tetsuro KIKUCHI, Masafumi TODA
  • Patent number: 11980690
    Abstract: Pharmaceutical formulation comprising centanafadine or a pharmaceutically acceptable salt thereof and an excipient, and related methods of manufacture and use, are disclosed.
    Type: Grant
    Filed: June 1, 2023
    Date of Patent: May 14, 2024
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Syed Asfar Mateen, Praveen Kumar Mididoddi, Shailly Mehrotra, Susan Elizabeth Shoaf, Salin Gupta, Kai Suzuki, Masahiro Hasegawa
  • Publication number: 20240148699
    Abstract: The present invention provides a oxazole compound represented by Formula (1), or a salt thereof: wherein R1 is an aryl group which may have one or more substituents; R2 is an aryl group or a nitrogen atom-containing heterocyclic group each of which may have one or more substituents; and W is a divalent group represented by —Y1-A1- or —Y2—C(?O)— wherein Y1 is a group such as —C(?O)—, A1 is a group such as a lower alkylene group, and Y2 is a group such as a piperazinediyl group. The oxazole compound has a specific inhibitory action against phosphodiesterase 4.
    Type: Application
    Filed: January 5, 2024
    Publication date: May 9, 2024
    Applicant: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Minoru Okada, Masaya Kato, Norifumi Sato, Tetsuyuki Uno, Hideki Kitagaki, Junpei Haruta, Hidetaka Hiyama, Tomonori Shibata
  • Publication number: 20240131169
    Abstract: The invention provides a CLIPTAC comprising: (a) a first portion comprising a ligand for an intracellular target protein; (b) a second portion comprising a ligand for an E3 ubiquitin ligase; and (c) a linker portion covalently coupling the first and second portions; wherein the linker comprises a covalent bond produced by a bioorthogonal click reaction between a compatible pair of reactive moieties. CLIPTAC precursor compositions and CLIPTAC precursors are also provided, together with pharmaceutical compositions comprising the CLIPTAC, CLIPTAC precursor compositions and CLIPTAC precursors, and methods of treatment using the same.
    Type: Application
    Filed: September 5, 2023
    Publication date: April 25, 2024
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Thomas Daniel HEIGHTMAN, Honorine LEBRAUD
  • Patent number: 11963971
    Abstract: Embodiments of the present invention provide solid oral dosage forms that upon daily administration to a subject provide plasma levels of decitabine with a 5-day AUC for decitabine that is equivalent to the 5-day AUC for a daily IV dose of decitabine of 20 mg/m2 administered as a one hour (1 h) infusion. Also provided according to embodiments of the present invention are solid oral dosage forms wherein upon daily administration to a subject provides a pharmacodynamic effect that is equivalent to the pharmacodynamic effect for a daily intravenous dose of decitabine of 20 mg/m2 administered as a one hour (1 h) infusion. Also provided are methods of treatment using a solid oral dosage form according to an embodiment of the invention.
    Type: Grant
    Filed: April 28, 2023
    Date of Patent: April 23, 2024
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Aram Oganesian, Nipun Davar, Jim Hwaicher Kou
  • Patent number: 11957691
    Abstract: An object of the present invention is to provide a combination drug that has remarkably excellent preventive and/or therapeutic effects on polycystic kidney disease. The present invention provides a drug for preventing and/or treating polycystic kidney disease comprising a combination of tolvaptan or a prodrug thereof with a somatostatin derivative, and a method for treating polycystic kidney disease using this drug.
    Type: Grant
    Filed: September 15, 2021
    Date of Patent: April 16, 2024
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroyuki Fujiki, Miki Aihara, Shizuo Kinoshita
  • Patent number: 11950615
    Abstract: An apparatus includes a food product, at least one ingestible device associated with the food product to communicate information and at least one coating material surrounding the at least one ingestible device is disclosed. The ingestible device is associated with an ingestible medication to be ingested in conjunction with the food product. The coating is configured to release the at least one ingestible device upon the occurrence of an event.
    Type: Grant
    Filed: November 10, 2021
    Date of Patent: April 9, 2024
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Lawrence Arne, Mark Zdeblick, Aditya Dua, George Savage, Robert Leichner, Jafar Shenasa, Patricia Johnson, Raymond Schmidt, Zahedeh Hatamkhany, Veeraperumanallu Muralidharan
  • Publication number: 20240109842
    Abstract: Provided is an acrylamide compound, which is useful for the promotion of platelet production from platelet progenitor cells such as megakaryocytes in vitro and represented by general formula [I]: wherein each symbol is as defined in the description.
    Type: Application
    Filed: December 8, 2020
    Publication date: April 4, 2024
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hideki HAYASHI, Ryosuke TAGA, Yuki SAKAMOTO, Nozomi KUWANO, Kurumi MINENO, Kazuhiro OHDACHI, Yusuke FUJIMORI
  • Patent number: 11939321
    Abstract: The invention provides a compound of formula (0): or a pharmaceutically acceptable salt, N-oxide or tautomer thereof; wherein: n is 1 or 2; X is CH or N; Y is selected from CH and C—F; Z is selected from C—Rz and N; R1 is selected from: -(Alk1)t-Cyc1; wherein t is 0 or 1; Optionally substituted C1-6 acyclic hydrocarbon groups R2 is selected from hydrogen; halogen; and C1-3 hydrocarbon groups optionally substituted with one or more fluorine atoms; R3 is hydrogen or a group L1-R7; R4 is selected from hydrogen; methoxy; and optionally substituted C1-3 alkyl; and R4a is selected from hydrogen and a C1-3 alkyl group; wherein Rz, Alk1, Cyc1, L1 and R7 are defined herein; provided that the compound is other than 6-benzyl-3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and 3-{2-[(2-methylpyrimidin-4-yl)amino]pyridin-4-yl}-7,8-dihydro-1,6-naphthyridin-5(6H)-one and salts and tautomers thereof.
    Type: Grant
    Filed: April 7, 2021
    Date of Patent: March 26, 2024
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Valerio Berdini, Ildiko Maria Buck, James Edward Harvey Day, Charlotte Mary Griffiths-Jones, Thomas Daniel Heightman, Steven Howard, Christopher William Murray, David Norton, Marc O'Reilly, Alison Jo-Anne Woolford, Michael Liam Cooke, David Cousin, Stuart Thomas Onions, Jonathan Martin Shannon, John Paul Watts
  • Patent number: 11932657
    Abstract: Provided is a novel heterocyclic compound having an aryl hydrocarbon receptor antagonist activity and useful for the promotion of platelet production, the compound being represented by the general formula [I]: wherein ring A, ring B, R1, R2, R3, R4, n, and X are as defined above, or a salt thereof.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: March 19, 2024
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Kazuhiro Ohdachi, Yusuke Fujimori, Naoya Makita, Noritaka Koseki, Hideki Hayashi, Yuki Sakamoto, Kurumi Mineno, Ryosuke Taga
  • Patent number: 11928614
    Abstract: Methods, systems and compositions that allow for treating a patient according to a patient customized therapeutic regimen are provided. Embodiments of the invention include obtaining dosage administration information from a patient and using the same to tailor a therapeutic regimen for the patient. Embodiments of the invention further include preparing and forwarding to the patient physical pharmaceutical dosages based on the customized therapeutic regimen.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: March 12, 2024
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Mark J. Zdeblick, Andrew Thompson, George M. Savage
  • Publication number: 20240076275
    Abstract: Provided is a crystal of a specific oxazole compound that has specific inhibitory activity against PDE4, and that shows excellent stability. Specifically, provided is a crystal of an oxazole compound represented by formula (5) wherein the crystal has peaks at diffraction angles)2?(°) of 9.6±0.2, 19.1±0.2, and 21.2±0.2 in an X-ray powder diffraction pattern measured using CuK? characteristic X-rays.
    Type: Application
    Filed: October 31, 2023
    Publication date: March 7, 2024
    Applicant: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Naohiko Kanai, Takayuki Yasutomi, Ryosuke Hirota
  • Publication number: 20240041774
    Abstract: An object of the present invention is to provide a freeze-dried aripiprazole powder formulation that exhibits good dispersibility and is easily dispersed into a homogenous suspension when reconstituted with water.
    Type: Application
    Filed: October 9, 2023
    Publication date: February 8, 2024
    Applicant: Otsuka Pharmaceutical Co., Ltd.
    Inventor: Shogo HIRAOKA
  • Patent number: 11890092
    Abstract: A system, a wearable device, and a method are provided which can increase the accuracy of physiological metrics while detecting if the patient ingested digital medicine and/or improve performance of the wearable device. The wearable device can comprise machine executable instructions that when executed by the processor, cause the processor to perform various algorithms, such as, for example, at least one of a step count algorithm, a body angle algorithm, a heart rate algorithm, a peak finder algorithm, an adaptive thresholding algorithm, a heart rate variability algorithm, a R-R cleaning Algorithm, a deltaR-R cleaning algorithm, a merge twin interval algorithm, a split tall intervals algorithm, an absorb short intervals algorithm, a bimodal detection algorithm, and a resting algorithm.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: February 6, 2024
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Robert Azevedo, Neraj P. Bobra, Aditya Dua, Ronny X. Li, William A. Weeks
  • Publication number: 20240009186
    Abstract: Provided is a solution suitable for oral administration of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one(compound (I)) or a salt thereof. A solution for oral administration containing compound (I) or a salt thereof and at least one compound selected from the group consisting of lactic acid, phosphoric acid, glycolic acid, malic acid, tartaric acid, citric acid, succinic acid and acetic acid and having pH 2.5-4.5.
    Type: Application
    Filed: March 27, 2023
    Publication date: January 11, 2024
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventor: Ayako OKAMOTO
  • Patent number: 11870508
    Abstract: A system for tracking a product from origin to destination is disclosed. The system includes a probe that comprises two plates, a power source and a processor. The power source is controlled by the processor to produce an oscillating output at the plates. Using the oscillating voltage, the probe interrogates a device through capacitive coupling. The device includes a control unit, a memory unit, and first and second materials physically associated with the device for communication using capacitive coupling. Information associated with the device is transferred from the device to the probe through capacitive coupling between the first and second materials and the first and second plates, respectively.
    Type: Grant
    Filed: January 18, 2022
    Date of Patent: January 9, 2024
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventor: Mark J. Zdeblick
  • Patent number: 11840512
    Abstract: Provided is a crystal of a specific oxazole compound that has specific inhibitory activity against PDE4, and that shows excellent stability. Specifically, provided is a crystal of an oxazole compound represented by formula (5) wherein the crystal has peaks at diffraction angles 2?(°) of 9.6±0.2, 19.1±0.2, and 21.2±0.2 in an X-ray powder diffraction pattern measured using CuK? characteristic X-rays.
    Type: Grant
    Filed: July 7, 2022
    Date of Patent: December 12, 2023
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Naohiko Kanai, Takayuki Yasutomi, Ryosuke Hirota
  • Publication number: 20230390399
    Abstract: An object of the present invention is to provide a storage-stable injectable preparation comprising a composition comprising a poorly soluble drug as an active ingredient and a dispersion medium. Another object of the present invention is to provide a compact, lightweight prefilled syringe by filling a syringe with the injectable preparation. The present invention provides an injectable preparation comprising a composition comprising a poorly soluble drug, a dispersion medium, and a specific suspending agent, the composition having a viscosity of 40 pascal-seconds or more in at least one point in the shear rate range of 0.01 to 0.02 s?1 end having a viscosity of 0.2 pascal-seconds or less in at least one point in the shear rate range of 900 to 1.000 s?1, as measured.
    Type: Application
    Filed: December 30, 2022
    Publication date: December 7, 2023
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Daiki KANEKO, Takakuni MATSUDA, Yusuke HOSHIKA
  • Publication number: 20230381194
    Abstract: This invention provides a suspension for oral administration comprising particles containing amorphous tolvaptan that can inhibit or delay crystallization of amorphous tolvaptan over time in the suspension, and stably maintain high solubility of tolvaptan and excellent absorbability of tolvaptan from the gastrointestinal tract; and a solid formulation for oral administration that can be suspended to prepare the suspension for oral administration at the time of use. This invention relates to a suspension for oral administration, in particular, a syrup, comprising (a) particles containing amorphous tolvaptan, (b) hydroxypropyl methylcellulose (HPMC), and (c) a solvent, wherein the amount of the HPMC (b) is 0.1 to 25% by weight based on the total weight of the suspension for oral administration.
    Type: Application
    Filed: August 2, 2023
    Publication date: November 30, 2023
    Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Akitsuna AKAGI, Kai SUZUKI, Atsuya NAKAMURA, Toru NISHIBAYASHI